Systemic and Mucosal Differences in HIV Burden, Immune, and Therapeutic Responses
暂无分享,去创建一个
Mardge H. Cohen | S. Wahl | W. Mack | P. Reichelderfer | J. Mestecky | M. Navazesh | J. Cohn | E. Janoff | A. Kovacs | H. Jenson | M. Redford | Shawna Christensen
[1] S. Wahl,et al. The mouth: a gateway or a trap for HIV? , 2010, AIDS.
[2] A. Wright,et al. Excretion of Human Immunodeficiency Virus Type 1 through Polarized Epithelium by Immunoglobulin A , 2008, Journal of Virology.
[3] Charles Poole,et al. Rethinking the heterosexual infectivity of HIV-1: a systematic review and meta-analysis. , 2008, The Lancet. Infectious diseases.
[4] Sarah S. Wilson,et al. Herpes Simplex Virus Downregulates Secretory Leukocyte Protease Inhibitor: a Novel Immune Evasion Mechanism , 2008, Journal of Virology.
[5] Susan Moir,et al. Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. , 2008, The Journal of allergy and clinical immunology.
[6] D. Boutolleau,et al. Multicenter Comparison of PCR Assays for Detection of Human Herpesvirus 6 DNA in Serum , 2008, Journal of Clinical Microbiology.
[7] John P. Moore,et al. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans , 2008, Nature Medicine.
[8] R. Kaul,et al. HIV-neutralizing immunoglobulin A and HIV-specific proliferation are independently associated with reduced HIV acquisition in Kenyan sex workers , 2008, AIDS.
[9] M. Kazatchkine,et al. Neutralizing monoclonal antibodies to human immunodeficiency virus type 1 do not inhibit viral transcytosis through mucosal epithelial cells. , 2008, Virology.
[10] A. Ding,et al. Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI , 2007, Nature Immunology.
[11] M. Clerici,et al. Hiv-specific secretory IgA in breast milk of HIV-positive mothers is not associated with protection against HIV transmission among breast-fed infants. , 2006, The Journal of pediatrics.
[12] S. Wahl,et al. HIV accomplices and adversaries in macrophage infection , 2006, Journal of leukocyte biology.
[13] D. Shugars,et al. Human Immunodeficiency Virus Type 1 Stimulates the Expression and Production of Secretory Leukocyte Protease Inhibitor (SLPI) in Oral Epithelial Cells: a Role for SLPI in Innate Mucosal Immunity , 2005, Journal of Virology.
[14] O. Laeyendecker,et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. , 2005, The Journal of infectious diseases.
[15] J. Mestecky,et al. Immunologic Uniqueness of the Genital Tract: Challenge for Vaccine Development , 2005, American journal of reproductive immunology.
[16] S. Wahl,et al. Secretory Leukocyte Protease Inhibitor Binds to Annexin II, a Cofactor for Macrophage HIV-1 Infection , 2004, The Journal of experimental medicine.
[17] R. Rogers,et al. Oral manifestations of sexually transmitted diseases. , 2004, Clinics in dermatology.
[18] M. Mulligan,et al. Paucity of antigen-specific IgA responses in sera and external secretions of HIV-type 1-infected individuals. , 2004, AIDS research and human retroviruses.
[19] J. Sallenave,et al. Antimicrobial peptides: mediators of innate immunity as templates for the development of novel anti-infective and immune therapeutics. , 2004, Current pharmaceutical design.
[20] A. Wald,et al. Genital herpes and human immunodeficiency virus: double trouble. , 2004, Bulletin of the World Health Organization.
[21] G. Slade,et al. Salivary Secretory Leukocyte Protease Inhibitor and Oral Candidiasis in Human Immunodeficiency Virus Type 1-Infected Persons , 2004, Infection and Immunity.
[22] Don Smith. HIV and herpes co-infection, an unfortunate partnership. , 2004, Journal of HIV therapy.
[23] J. Dilley,et al. Risk of HIV infection attributable to oral sex among men who have sex with men and in the population of men who have sex with men. , 2002, AIDS.
[24] B. Richardson,et al. Salivary secretory leukocyte protease inhibitor is associated with reduced transmission of human immunodeficiency virus type 1 through breast milk. , 2002, The Journal of infectious diseases.
[25] L. Lopalco,et al. Cross-clade HIV-1-specific neutralizing IgA in mucosal and systemic compartments of HIV-1-exposed, persistently seronegative subjects. , 2002, Journal of acquired immune deficiency syndromes.
[26] Mardge H. Cohen,et al. Determinants of HIV-1 shedding in the genital tract of women , 2001, The Lancet.
[27] J. Bremer,et al. Longitudinal Variability of Human Immunodeficiency Virus Type 1 RNA Viral Load Measurements by Nucleic Acid Sequence-Based Amplification and NucliSens Assays in a Large Multicenter Study , 2001, Journal of Clinical Microbiology.
[28] L. Lopalco,et al. Mucosal IgA in exposed, uninfected subjects: evidence for a role in protection against HIV infection. , 2001, AIDS.
[29] L. Kuhn,et al. Secretory leukocyte protease inhibitor in vaginal fluids and perinatal human immunodeficiency virus type 1 transmission. , 2001, The Journal of infectious diseases.
[30] P. Cristoforoni,et al. Effects of Human Papillomavirus‐Associated Cells on Human Immunodeficiency Virus Gene Expression , 2000, Obstetrics and gynecology.
[31] F. Lucht,et al. Neutralization of human immunodeficiency virus type 1 (HIV-1) mediated by parotid IgA of HIV-1-infected patients. , 2000, The Journal of infectious diseases.
[32] O. Bagasra,et al. Multicenter Comparison of PCR Assays for Detection of Human Herpesvirus 8 DNA in Semen , 1999, Journal of Clinical Microbiology.
[33] S. Huong,et al. Identification of human cytomegalovirus target sequences in the human immunodeficiency virus long terminal repeat. Potential role of IE2-86 binding to sequences between -120 and -20 in promoter transactivation. , 1999, Journal of human virology.
[34] J. Orenstein,et al. The macrophage origin of the HIV-expressing multinucleated giant cells in hyperplastic tonsils and adenoids. , 1999, Ultrastructural pathology.
[35] L. Kalish,et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. , 1999, Journal of the National Cancer Institute.
[36] D. Isenberg,et al. Structural basis of the gp120 superantigen-binding site on human immunoglobulins. , 1998, Journal of immunology.
[37] M. Schluchter,et al. Maternal and perinatal factors related to maternal-infant transmission of HIV-1 in the P2C2 HIV study : The role of EBV shedding , 1998 .
[38] L. Mortimer,et al. Cysteine proteases of Trichomonas vaginalis degrade secretory leukocyte protease inhibitor. , 1998, The Journal of infectious diseases.
[39] M. Gisslén,et al. Increased cerebrospinal fluid ganglioside GD3 concentrations as a marker of microglial activation in HIV type 1 infection. , 1998, AIDS research and human retroviruses.
[40] D. Ho,et al. HIV-1 Antigen–specific and –nonspecific B Cell Responses Are Sensitive to Combination Antiretroviral Therapy , 1998, The Journal of experimental medicine.
[41] S. Wahl,et al. The role of the oral environment in HIV-1 transmission. , 1998, Journal of the American Dental Association.
[42] T. Schacker,et al. Frequent recovery of HIV-1 from genital herpes simplex virus lesions in HIV-1-infected men. , 1998, JAMA.
[43] D. Anderson,et al. Quantitation of mediators of inflammation and immunity in genital tract secretions and their relevance to HIV type 1 transmission. , 1998, AIDS research and human retroviruses.
[44] Joseph Feldman,et al. The Women's Interagency HIV Study , 1998 .
[45] R. Silverstein,et al. Identification of a CD36-related Thrombospondin 1–binding Domain in HIV-1 Envelope Glycoprotein gp120: Relationship to HIV-1–specific Inhibitory Factors in Human Saliva , 1998, The Journal of experimental medicine.
[46] S. Wahl,et al. Inhibition of human immunodeficiency virus type 1 infectivity by secretory leukocyte protease inhibitor occurs prior to viral reverse transcription. , 1997, Blood.
[47] Phillip D. Smith,et al. IMMUNOBIOLOGY OF MUCOSAL HIV-1 INFECTION , 1996 .
[48] T. Schacker,et al. Clinical and Epidemiologic Features of Primary HIV Infection , 1996, Annals of Internal Medicine.
[49] P. D. Smith,et al. Modulation of human immunodeficiency virus type 1 infection of human monocytes by IgA. , 1995, The Journal of infectious diseases.
[50] T. Lehner,et al. Comparative investigation of Langerhans' cells and potential receptors for HIV in oral, genitourinary and rectal epithelia. , 1995, Immunology.
[51] D. Dripps,et al. Secretory leukocyte protease inhibitor: a human saliva protein exhibiting anti-human immunodeficiency virus 1 activity in vitro. , 1995, The Journal of clinical investigation.
[52] R. Crystal,et al. Anti-neutrophil elastase defense of the normal human respiratory epithelial surface provided by the secretory leukoprotease inhibitor. , 1991, The Journal of clinical investigation.
[53] Noel R. Rose,et al. Manual of clinical laboratory immunology , 2002 .
[54] L. Kalish,et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. , 1998, Epidemiology.
[55] M. Schluchter,et al. Maternal and perinatal factors related to maternal-infant transmission of HIV-1 in the P2C2 HIV study: the role of EBV shedding. Pediatric Pulmonary and Cardiovascular Complications of Vertically Transmitted HIV-1 Infection (P2C2 HIV) Study Group. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[56] K. Holmes,et al. Nonspecific vaginitis: Diagnostic criteria and microbial and epidemiologic associations , 1983 .
[57] D. Pittet,et al. COOK County Hospital. , 1956, Medical times.